Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis.
TA, C., LMT, d.S., A, N., GCL, C., M, A., LA, A., 3rd, C.W., & J, H. (2026). Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis.. Heart failure reviews. https://doi.org/10.1007/s10741-026-10641-3
TA C, LMT dS, A N, GCL C, M A, LA A, et al. Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis.. Heart failure reviews. 2026; doi: 10.1007/s10741-026-10641-3
TA C, LMT dS, A N, et al. Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis.[J]. Heart failure reviews. 2026. DOI: 10.1007/s10741-026-10641-3.
@article{ta2026,
author = {Costa TA and de Sousa LMT and Nogueira A and Chagas GCL and Abreu M and Allen LA and Cornwell WK 3rd and Harrington J},
title = {Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis.},
journal = {Heart failure reviews},
year = {2026},
doi = {10.1007/s10741-026-10641-3},
note = {PMID: 42249978},
}
TY - JOUR AU - Costa TA AU - de Sousa LMT AU - Nogueira A AU - Chagas GCL AU - Abreu M AU - Allen LA AU - Cornwell WK 3rd AU - Harrington J TI - Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis. T2 - Heart failure reviews PY - 2026 DO - 10.1007/s10741-026-10641-3 AN - PMID:42249978 ER -
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are recommended for multiple populations-type 2 diabetes (T2D), chronic kidney disease, and heart failure-but their role after heart transplant (HTX) remains unclear. We searched PubMed, Cochrane, and Embase for studies of HTX recipients with T2D comparing outcomes in SGLT2i users vs. non-users. Outcomes of interest were all-cause mortality, urinary tract infection (UTI), and estimated glomerular filtration rate (eGFR) change from baseline. Odds ratios (ORs) and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) were pooled using a random-effects model for binary outcomes. Three retrospective observational studies were included in the all-cause mortality meta-analysis, four in the UTI incidence meta-analysis, and five in the qualitative analysis evaluating eGFR change (n = 3,564). Mean follow-up ranged from 9 to 83 months. SGLT2i use was associated with a lower risk of all-cause mortality compared with non-use in both unadjusted (OR 0.43; 95% CI 0.26-0.71; p < 0.001; I² = 79%) and adjusted analyses (aHR 0.69; 95% CI 0.51-0.93; p = 0.02; I² = 20%), without increasing the risk of UTI (OR 0.77; 95% CI 0.14-4.05; p = 0.75; I² = 48%). Most studies suggested stable or increased eGFR from baseline with SGLT2i exposure. SGLT2i use, compared with non-use, was associated with lower all-cause mortality without an increased incidence of UTIs in HTX recipients with T2D. Additionally, the pooled data suggest a possible renal benefit. The totality of these observational data, despite their limitations, provide important context for ongoing SGLT2i use following HTX.